Market News

Foundation Asset Management LP Has Trimmed Its Stake in Theravance Biopharma (TBPH) by $638,316 as Valuation Rose; Neumann Capital Management Has Decreased Holding in Express Scripts Hldg Co (ESRX) by $544,320

David Charney decreased its stake in Theravance Biopharma Inc (TBPH) by 4.16% based on its latest 2017Q3 regulatory filing with the SEC. Foundation Asset Management Lp sold 18,774 shares as the company’s stock rose 9.03% with the market. The hedge fund run by David Charney held 432,532 shares of the health care company at the end of 2017Q3, valued at $14.81 million, down from 451,306 at the end of the previous reported quarter. Foundation Asset Management Lp who had been investing in Theravance Biopharma Inc for a number of months, seems to be less bullish one the $1.55B market cap company. The stock increased 1.67% or $0.47 during the last trading session, reaching $28.61. About 31,404 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has risen 89.85% since February 14, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.

Neumann Capital Management Llc decreased its stake in Express Scripts Hldg Co (ESRX) by 73.28% based on its latest 2017Q3 regulatory filing with the SEC. Neumann Capital Management Llc sold 8,640 shares as the company’s stock declined 14.09% while stock markets rallied. The institutional investor held 3,150 shares of the medical and nursing services company at the end of 2017Q3, valued at $199,000, down from 11,790 at the end of the previous reported quarter. Neumann Capital Management Llc who had been investing in Express Scripts Hldg Co for a number of months, seems to be less bullish one the $41.84B market cap company. The stock increased 0.39% or $0.29 during the last trading session, reaching $73.88. About 1.13M shares traded. Express Scripts Holding Company (NASDAQ:ESRX) has declined 16.92% since February 14, 2017 and is downtrending. It has underperformed by 33.62% the S&P500.

Neumann Capital Management Llc, which manages about $305.78 million and $161.53 million US Long portfolio, upped its stake in Wisdomtree Tr (DLS) by 12,940 shares to 29,096 shares, valued at $2.15 million in 2017Q3, according to the filing.

Investors sentiment increased to 0.62 in Q3 2017. Its up 0.06, from 0.56 in 2017Q2. It is positive, as 66 investors sold ESRX shares while 414 reduced holdings. 72 funds opened positions while 224 raised stakes. 486.80 million shares or 2.59% less from 499.72 million shares in 2017Q2 were reported. Global X Management Com Ltd Liability accumulated 0.02% or 12,102 shares. Whitnell & holds 1.34% in Express Scripts Holding Company (NASDAQ:ESRX) or 48,686 shares. First Midwest Natl Bank Trust Division invested in 0.03% or 4,529 shares. Old Mutual Glob Investors (Uk) holds 0.27% or 407,380 shares. Perigon Wealth Mgmt Lc accumulated 935 shares. Roberts Glore & Company Il holds 7,260 shares or 0.3% of its portfolio. Sky Inv Gp Llc, a Connecticut-based fund reported 26,619 shares. Peoples Service reported 2,600 shares. Hanson Mcclain owns 464 shares. Rockshelter Mngmt Ltd Com reported 125,674 shares stake. Selway Asset Mngmt accumulated 1.86% or 50,700 shares. Forte Capital Lc Adv holds 43,168 shares or 0.88% of its portfolio. Tokio Marine Asset owns 4,778 shares. Boston Ltd Liability holds 5,491 shares. Meyer Handelman Co holds 15,412 shares or 0.04% of its portfolio.

Among 24 analysts covering Express Scripts (NASDAQ:ESRX), 11 have Buy rating, 4 Sell and 9 Hold. Therefore 46% are positive. Express Scripts had 56 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, May 26 by Jefferies. Mizuho maintained the stock with “Hold” rating in Wednesday, January 24 report. The firm earned “Hold” rating on Wednesday, October 25 by RBC Capital Markets. The company was upgraded on Monday, April 4 by Cowen & Co. Barclays Capital maintained Express Scripts Holding Company (NASDAQ:ESRX) rating on Thursday, February 18. Barclays Capital has “Overweight” rating and $85 target. The stock has “Overweight” rating by Barclays Capital on Wednesday, July 27. The stock of Express Scripts Holding Company (NASDAQ:ESRX) has “Outperform” rating given on Tuesday, April 26 by Credit Suisse. The rating was upgraded by RBC Capital Markets on Wednesday, January 31 to “Outperform”. As per Wednesday, March 15, the company rating was downgraded by Wells Fargo. The firm has “Market Perform” rating given on Wednesday, March 23 by Leerink Swann.

Investors sentiment decreased to 1.32 in 2017 Q3. Its down 0.46, from 1.78 in 2017Q2. It is negative, as 13 investors sold TBPH shares while 18 reduced holdings. 7 funds opened positions while 34 raised stakes. 35.46 million shares or 3.52% more from 34.25 million shares in 2017Q2 were reported. Sei Invs Company has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Rock Springs Management Limited Partnership invested in 1.02% or 644,400 shares. Moneta Group Advsr Llc holds 0.05% in Theravance Biopharma, Inc. (NASDAQ:TBPH) or 8,742 shares. Nj State Employees Deferred Compensation Plan stated it has 0.15% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Ubs Asset Mgmt Americas Inc holds 23,998 shares or 0% of its portfolio. Bnp Paribas Arbitrage Sa holds 4,868 shares. Senzar Asset Management Lc stated it has 1.52% in Theravance Biopharma, Inc. (NASDAQ:TBPH). State Street invested in 913,836 shares or 0% of the stock. Savings Bank Of America Corporation De invested in 60,584 shares or 0% of the stock. Vanguard Grp Inc Inc accumulated 3.29 million shares or 0.01% of the stock. 950,000 are owned by Cormorant Asset Mngmt Ltd Liability. Old West Inv Management Limited Liability invested in 2.05% or 113,942 shares. Blackrock holds 0.01% or 3.81M shares in its portfolio. The Massachusetts-based Geode Cap Mgmt Limited Liability Corporation has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Citigroup holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 9,692 shares.

Since September 6, 2017, it had 0 buys, and 1 sale for $451,350 activity.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 earnings per share, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual earnings per share reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *